Metal-dependent amyloid β-degrading catalytic antibody construct

J Biotechnol. 2014 Jun 20:180:17-22. doi: 10.1016/j.jbiotec.2014.03.026. Epub 2014 Apr 1.

Abstract

Catalytic antibodies (catabodies) that degrade target antigens rapidly are rare. We describe the metal-dependence of catabody construct 2E6, an engineered heterodimer of immunoglobulin light chain variable domains that hydrolyzes amyloid β peptides (Aβ) specifically. In addition to the electrophilic phosphonate inhibitor of serine proteases, the metal chelators ethylenediaminetetraacetic acid (EDTA) and 1,10-phenanthroline completely inhibited the hydrolysis of Aβ by catabody 2E6. Formation of catabody-electrophilic phosphonate inhibitor adducts was unaffected by EDTA, suggesting that the metal exerts a favorable effect on a catalytic step after the initial catabody nucleophilic attack on Aβ. The EDTA inactivated catabody failed to disaggregate fibrillar Aβ, indicating the functional importance of the Aβ hydrolytic activity. Treating the EDTA-inactivated catabody with Zn(2+) or Co(2+) restored the Aβ hydrolytic activity, and Zn(2+)-induced catabody conformational transitions were evident by fluorescence emission spectroscopy. The studies reveal the absolute catabody dependence on a metal cofactor.

Keywords: Alzheimer disease; Amyloid β clearance; Catalytic antibody light chain; Metal activation.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Alzheimer Disease
  • Amyloid beta-Peptides / chemistry
  • Amyloid beta-Peptides / metabolism*
  • Antibodies, Catalytic / chemistry*
  • Antibodies, Catalytic / drug effects
  • Antibodies, Catalytic / metabolism*
  • Chelating Agents / pharmacology
  • Copper / chemistry
  • Copper / metabolism*
  • Copper / pharmacology
  • Edetic Acid / pharmacology
  • Humans
  • Hydrolysis
  • Zinc / chemistry
  • Zinc / metabolism*
  • Zinc / pharmacology

Substances

  • Amyloid beta-Peptides
  • Antibodies, Catalytic
  • Chelating Agents
  • Copper
  • Edetic Acid
  • Zinc